Gastroesophageal-junction Cancer research hub

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

This study looks at a new medicine called HLX22, combined with standard treatments, for people newly diagnosed with a certain type of stomach and food pipe cancer. It aims to see how well it works and if it's safe compared to current treatments.